2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12D.01 Clinical Outcomes of Patients with HER2-Mutant NSCLC in Real-World Settings: A Systematic Literature Review

EP.12D.01 Clinical Outcomes of Patients with HER2-Mutant NSCLC in Real-World Settings: A Systematic Literature Review

Pdf Summary

This document presents a systematic literature review (SLR) on clinical outcomes for patients with advanced non-small cell lung cancer (NSCLC) harboring mutations in the human epidermal growth factor receptor 2 (HER2), also known as Erb-B2 receptor tyrosine kinase 2 (ERBB2). HER2 mutations are seen in about 2% to 4% of NSCLC cases and are linked with poor prognosis. The SLR, focusing on studies from 2019 to 2023, aimed to identify the frequency of HER2 mutations, assess clinical outcomes compared to the general NSCLC population, and evaluate potential prognostic biomarkers and adverse events specific to HER2-mutant NSCLC.<br /><br />The review included 66 studies, revealing that HER2 mutations in NSCLC patients occur at a frequency of 1% to 8.7%. Exon 20 insertions (ex20ins) are the most common type of HER2 alterations. The overall response rate (ORR) among these patients varied between 0% to 57.1%, with a poorer response noted in those receiving treatments like EGFR TKI and immunotherapy compared to chemotherapy-containing regimens. Similarly, median progression-free survival (PFS) was generally longer for patients with non-YVMA mutations or those receiving chemotherapy, while shorter PFS was observed in patients with ex20ins mutations or those treated with EGFR TKI therapies. Median overall survival (OS) displayed a range from 5.9 to 82.8 months across studies, reflecting better outcomes for those with chemotherapy regimens and poorer outcomes for those with HER2 ex20ins mutations or EGFR TKI therapies.<br /><br />The findings highlight a need for additional research to validate these associations and address the evidence gaps, particularly regarding adverse events and prognostic biomarkers, for therapies targeting HER2-mutant NSCLC.

Asset Subtitle

Xiuning Le

Meta Tag

Speaker Xiuning Le

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

systematic literature review

advanced non-small cell lung cancer

NSCLC

HER2 mutations

ERBB2

prognostic biomarkers

exon 20 insertions

clinical outcomes

progression-free survival

overall survival